MA42656A - Vaccin vivant atténué comprenant des mutations de polymérase virale pour le traitement et la prévention de virus de la grippe canine - Google Patents

Vaccin vivant atténué comprenant des mutations de polymérase virale pour le traitement et la prévention de virus de la grippe canine

Info

Publication number
MA42656A
MA42656A MA042656A MA42656A MA42656A MA 42656 A MA42656 A MA 42656A MA 042656 A MA042656 A MA 042656A MA 42656 A MA42656 A MA 42656A MA 42656 A MA42656 A MA 42656A
Authority
MA
Morocco
Prior art keywords
prevention
treatment
influenza virus
live attenuated
vaccine containing
Prior art date
Application number
MA042656A
Other languages
English (en)
Inventor
Luis Martinez-Sobrido
Aitor Nogales-Gonzalez
Colin Parrish
Original Assignee
Univ Cornell
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell, Univ Rochester filed Critical Univ Cornell
Publication of MA42656A publication Critical patent/MA42656A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA042656A 2015-08-20 2016-08-19 Vaccin vivant atténué comprenant des mutations de polymérase virale pour le traitement et la prévention de virus de la grippe canine MA42656A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562207571P 2015-08-20 2015-08-20

Publications (1)

Publication Number Publication Date
MA42656A true MA42656A (fr) 2018-06-27

Family

ID=56801864

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042656A MA42656A (fr) 2015-08-20 2016-08-19 Vaccin vivant atténué comprenant des mutations de polymérase virale pour le traitement et la prévention de virus de la grippe canine

Country Status (6)

Country Link
US (2) US10478489B2 (fr)
EP (1) EP3337504A1 (fr)
AU (1) AU2016308917A1 (fr)
CA (1) CA2995382A1 (fr)
MA (1) MA42656A (fr)
WO (1) WO2017031404A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017031408A1 (fr) 2015-08-20 2017-02-23 University Of Rochester Virus à cycle unique pour le développement de vaccins contre la grippe canine
AU2016308917A1 (en) * 2015-08-20 2018-03-15 Cornell University Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
WO2017031401A2 (fr) 2015-08-20 2017-02-23 University Of Rochester Virus ns1 tronqué pour le développement de vaccins contre la grippe canine
EP3463439B1 (fr) 2016-06-03 2022-08-03 University of Rochester Vaccins vivants atténués contre le virus de la grippe équine
AR114410A1 (es) 2018-02-27 2020-09-02 Univ Rochester Vacuna multivalente contra influenza viva atenuada para prevenir y controlar el virus influenza equino (vie) en caballos
CN113173976B (zh) * 2021-06-03 2022-07-12 北京市农林科学院 一种犬流感病毒h3亚型ha蛋白、其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
JPH11512609A (ja) 1995-09-27 1999-11-02 アメリカ合衆国 クローン化されたヌクレオチド配列からの感染性ＲＳウイルス（ｒｅｓｐｉｒａｔｏｒｙ ｓｙｎｃｙｔｉａｌ ｖｉｒｕｓ）の生産
BR9710363A (pt) 1996-07-15 2000-01-11 Us Gov Health & Human Serv "vìrus sincicial respirátorio recombinante infeccioso isolado, partìcula do mesmo, processos para estimular o sistema imunológico de um indivìduo para induzir proteção contra o vìrus sincicial respiratório e para produzir uma partìcula de vìrus sincicial respiratório recombinante, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante composição e ceta de vìrus sincicial respiratório recombinante"
CA2265554A1 (fr) 1996-09-27 1998-04-02 American Cyanamid Company Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales
BR9809456B1 (pt) 1997-05-23 2011-06-28 molécula isolada de polinucleotìdeo, composição de célula ou isenta de célula, partìcula de piv infeciosa, atenuada e imunogênica, e, composição imunogênica.
CA2295858C (fr) 1997-07-11 2011-05-10 Yale University Rhabdovirus a enveloppes remanipulees
JP2001517448A (ja) 1997-09-19 2001-10-09 アメリカン・サイアナミド・カンパニー 弱毒化呼吸合胞体ウイルス
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7425336B2 (en) * 2005-08-25 2008-09-16 Mevial Limited Canine influenza vaccines
JP4667507B2 (ja) 2005-10-07 2011-04-13 ファイザー・プロダクツ・インク イヌインフルエンザを治療するワクチンおよび方法
KR100850545B1 (ko) 2007-10-30 2008-08-05 주식회사 에니멀제네틱스 신규한 개 인플루엔자 바이러스 및 이의 백신
US8475807B2 (en) * 2008-03-13 2013-07-02 University Of Maryland College Park Avian influenza virus live attenuated vaccine and uses thereof
TW201125984A (en) * 2009-10-09 2011-08-01 Univ New York State Res Found Attenuated influenza viruses and vaccines
WO2013030176A2 (fr) 2011-09-02 2013-03-07 Westfälische Wilhelms-Universität Münster Virus grippaux vivants atténués
WO2015010073A1 (fr) 2013-07-19 2015-01-22 University Of Rochester Vaccins atténués contre la grippe et leurs utilisations
AU2016308917A1 (en) * 2015-08-20 2018-03-15 Cornell University Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
WO2017031408A1 (fr) 2015-08-20 2017-02-23 University Of Rochester Virus à cycle unique pour le développement de vaccins contre la grippe canine
EP3463439B1 (fr) 2016-06-03 2022-08-03 University of Rochester Vaccins vivants atténués contre le virus de la grippe équine

Also Published As

Publication number Publication date
EP3337504A1 (fr) 2018-06-27
US10478489B2 (en) 2019-11-19
WO2017031404A1 (fr) 2017-02-23
AU2016308917A1 (en) 2018-03-15
US20180243401A1 (en) 2018-08-30
US11065326B2 (en) 2021-07-20
US20200023055A1 (en) 2020-01-23
CA2995382A1 (fr) 2017-02-23

Similar Documents

Publication Publication Date Title
MA42656A (fr) Vaccin vivant atténué comprenant des mutations de polymérase virale pour le traitement et la prévention de virus de la grippe canine
DK3597646T3 (da) Terapeutiske forbindelser egnede til den profylaktiske eller terapeutiske behandling af en hiv-virusinfektion
MA50335A (fr) Vaccins à acide nucléique contre des virus respiratoires
HK1251554A1 (zh) 用於治療和預防病毒感染的新的取代的氨基噻唑並嘧啶二酮
HK1248711A1 (zh) 用於治療和預防病毒感染的新的取代的氨基噻唑並嘧啶二酮
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
CL2017000064A1 (es) Vacunas contra virus influenza y usos de las mismas
PH12017500207A1 (en) Indoles for use in influenza virus infection
IL244431A0 (en) Pharmacy methods and preparations for the treatment of hepatitis b virus infection
CL2017000063A1 (es) Vacunas contra virus influenza y usos de las mismas
ZA202003155B (en) Liquid vaccines of live enveloped viruses
DK3261642T3 (da) Quinolinderivater til anvendelse ved behandling eller forebyggelse af virusinfektioner
HK1251616A1 (zh) 用於預防和/或治療感染性疾病以及用於治療腫瘤疾病的減毒流感病毒載體
HK1251010A1 (zh) 用於治療乙型肝炎病毒(hbv)感染的試劑及用途
FI3118211T3 (fi) Amidiyhdisteitä, valmistusmenetelmiä ja niiden käyttö aineina hoidettaessa ja ennaltaehkäistäessä rna:ta ja/tai dna:ta sisältävien viruksien aiheuttamia sairauksia sekä samanaikaisia sairauksia
HK1252343A1 (zh) 用於治療病毒感染的組合物和方法
BR112014025339A2 (pt) Método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo
HK1244506A1 (zh) 用於流感病毒的減弱活疫苗
MA45477A (fr) Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire
EP3484511A4 (fr) Compositions vaccinales pour le traitement d'une infection par le virus zika
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
MA45994A (fr) Vaccins contre des virus
SG11201605440TA (en) Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
MY184269A (en) Broad-spectrum anti-influenza virus therapeutic peptides
EA201792482A1 (ru) Соединения-пептидомиметики, нейтрализующие вирус гриппа